Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.
Triple-negative breast cancer
classification
molecular
review
targeted
therapies
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
06
02
2020
revised:
01
04
2020
accepted:
06
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Triple-negative breast cancer (TNBC) is an extremely diverse group of breast tumors, with aggressive clinical behavior, higher rates of distant recurrence and worse overall survival compared to other types of breast cancers. The genetic, transcriptional histological and clinical heterogeneity of this disease has been an obstacle in the progression of targeted therapeutic approaches, as a ubiquitous TNBC marker has not yet been discerned. In terms of that, current studies focus on the classification of TNBC tumors in subgroups with similar characteristics in order to develop a treatment specialized for each group of patients. To date, a series of gene expression profiles analysis in order to identify the different molecular subtypes have been used. Complementary DNA microarrays, PAM50 assays, DNA and RNA sequencing as well as immunohistochemical analysis are some of the methods utilized to classify TNBC tumors. In 2012, the Cancer Genome Atlas (TCGA) Research Network conducted a major analysis of breast cancers using six different platforms, the genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays, in order to assort the tumors in homogenous subgroups. Since then, an increasing number of breast cancer data sets are being examined in an attempt to distinguish the classification with biological interpretation and clinical implementation. In this review, the progress in molecular subtyping of TNBC is discussed, providing a brief insight in novel TNBC biomarkers and therapeutic strategies.
Identifiants
pubmed: 32606140
pii: 34/4/1715
doi: 10.21873/invivo.11965
pmc: PMC7439891
doi:
Substances chimiques
RNA, Messenger
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1715-1727Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Breast Cancer Res. 2014 Jan 22;16(1):R7
pubmed: 24451109
Tumour Biol. 2016 Aug;37(8):10133-40
pubmed: 26825981
Breast Cancer Res Treat. 2012 Jul;134(1):21-30
pubmed: 22234518
Ann Surg Oncol. 2015 Jan;22(1):82-9
pubmed: 25145503
Clin Cancer Res. 2005 Aug 15;11(16):5678-85
pubmed: 16115903
Arch Pathol Lab Med. 2009 Nov;133(11):1822-5
pubmed: 19886718
Cancer Genomics Proteomics. 2019 Jul-Aug;16(4):257-266
pubmed: 31243106
Medicine (Baltimore). 2016 Aug;95(35):e4614
pubmed: 27583878
J Pathol. 2016 Apr;238(5):677-88
pubmed: 26806567
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
Oncogene. 2005 Jul 7;24(29):4660-71
pubmed: 15897907
Breast Cancer Res Treat. 2014 Nov;148(2):415-21
pubmed: 25342642
Mod Pathol. 2007 Nov;20(11):1200-7
pubmed: 17885672
Cancer Inform. 2012;11:147-56
pubmed: 22872785
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
Am J Pathol. 2017 Oct;187(10):2139-2151
pubmed: 28736315
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Am J Surg Pathol. 2008 Apr;32(4):544-52
pubmed: 18300793
Pharmacol Ther. 2015 Dec;156:90-101
pubmed: 26388292
Arch Pathol Lab Med. 2011 Jan;135(1):123-30
pubmed: 21204718
Horm Cancer. 2015 Dec;6(5-6):206-13
pubmed: 26201402
Breast Cancer Res. 2013 Nov 25;15(6):R112
pubmed: 24274653
Clin Transl Oncol. 2014 Mar;16(3):280-4
pubmed: 23982851
NPJ Breast Cancer. 2016 Nov 16;2:16036
pubmed: 28721389
Cancer Res. 2006 May 1;66(9):4636-44
pubmed: 16651414
Breast Cancer Res Treat. 2014 Dec;148(3):467-76
pubmed: 25361613
Anticancer Res. 2019 Oct;39(10):5285-5296
pubmed: 31570423
Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Lancet Oncol. 2014 Dec;15(13):e625-e634
pubmed: 25456381
AJR Am J Roentgenol. 2012 Aug;199(2):458-64
pubmed: 22826413
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Anticancer Res. 2019 Jul;39(7):3863-3869
pubmed: 31262914
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Breast Cancer Res. 2010;12(4):207
pubmed: 20804570
Am J Clin Pathol. 2000 May;113(suppl_1):S3-18
pubmed: 11993707
J Natl Cancer Inst. 2014 Jan;106(1):djt319
pubmed: 24273215
Anticancer Res. 2014 Mar;34(3):1261-7
pubmed: 24596370
Sci Rep. 2019 Feb 7;9(1):1538
pubmed: 30733547
Clin Cancer Res. 2005 Jun 1;11(11):4003-11
pubmed: 15930334
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
Nat Med. 2008 May;14(5):518-27
pubmed: 18438415
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Cell Physiol Biochem. 2016;38(3):1003-14
pubmed: 26938985
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
Expert Rev Anticancer Ther. 2010 Feb;10(2):199-207
pubmed: 20131996
J Clin Oncol. 2006 Dec 20;24(36):5652-7
pubmed: 17116942
Am J Cancer Res. 2016 Sep 01;6(9):1864-1872
pubmed: 27725895
Cancer. 2007 Aug 15;110(4):876-84
pubmed: 17620276
Cancer Cell. 2002 Nov;2(5):367-76
pubmed: 12450792
Breast Cancer (Dove Med Press). 2016 Oct 06;8:183-197
pubmed: 27785100
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Cell Cycle. 2016;15(8):1046-59
pubmed: 26919310
Mod Pathol. 2016 Nov;29(11):1292-1305
pubmed: 27491809
Rev Prat. 2013 Dec;63(10):1408-14
pubmed: 24579340
Anticancer Res. 2019 Jun;39(6):3111-3119
pubmed: 31177156
J Clin Oncol. 2015 Jan 1;33(1):13-21
pubmed: 25092775
Cancer Lett. 2016 Nov 1;382(1):77-85
pubmed: 26965997
Lab Invest. 2008 May;88(5):459-63
pubmed: 18379567
Breast Cancer Res Treat. 2014 Apr;144(2):223-32
pubmed: 24557340
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
Adv Anat Pathol. 2015 Sep;22(5):306-13
pubmed: 26262513
Jpn J Clin Oncol. 2012 May;42(5):375-86
pubmed: 22450930
Mod Pathol. 2015 Mar;28(3):340-51
pubmed: 25412848
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18740-4
pubmed: 19841262
Breast Cancer Res Treat. 2009 May;115(2):423-8
pubmed: 18543098
BMC Cancer. 2013 Feb 01;13:46
pubmed: 23374397
Breast Cancer Res Treat. 2014 Aug;146(3):567-72
pubmed: 25001611
Expert Rev Mol Diagn. 2016;16(1):39-50
pubmed: 26568208
Ther Adv Med Oncol. 2016 Sep;8(5):351-9
pubmed: 27583027
Am J Surg Pathol. 2015 Nov;39(11):1458-67
pubmed: 26291510
Breast. 2015 Dec;24(6):723-31
pubmed: 26392199
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):299-313
pubmed: 28870998
Clin Breast Cancer. 2015 Dec;15(6):473-481.e3
pubmed: 26051240
Cancers (Basel). 2017 Feb 24;9(3):
pubmed: 28245550
Curr Treat Options Oncol. 2017 Nov 6;18(11):68
pubmed: 29110096
J Pathol. 2014 Jan;232(2):142-50
pubmed: 24114677
Breast Care (Basel). 2013 May;8(2):149-54
pubmed: 24415964
Pathol Oncol Res. 2009 Mar;15(1):41-5
pubmed: 18752048
J Clin Oncol. 2010 Mar 1;28(7):1145-53
pubmed: 20100965
Nat Rev Clin Oncol. 2013 Dec;10(12):688-96
pubmed: 24129347
Oncotarget. 2015 May 30;6(15):12890-908
pubmed: 25973541
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Clin Cancer Res. 2014 Feb 15;20(4):782-90
pubmed: 24536073
J Clin Oncol. 2005 Oct 10;23(29):7350-60
pubmed: 16145060
J Clin Oncol. 2013 Jul 10;31(20):2586-92
pubmed: 23733761
Mod Pathol. 2017 Jan;30(1):69-84
pubmed: 27713419
Breast Dis. 2010;32(1-2):73-84
pubmed: 21778575
J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
pubmed: 21191117
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Histopathology. 2012 May;60(6B):E115-30
pubmed: 22486256
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
BMC Genomics. 2006 Apr 27;7:96
pubmed: 16643655
Clin Cancer Res. 2013 Oct 1;19(19):5533-40
pubmed: 23948975
Oncologist. 2013;18(2):123-33
pubmed: 23404817